This article is a review of this winter's common infections and their treatments. As infectious agents become more aggressive and more resistant, new medications are needed to fight them. The recent outbreak of the H1N1 ("swine flu") influenza strain has increased, by several-fold, the use of the oral antiviral Tamiflu (oseltamivir) and Relenza (zenavimir). -As resistant skin and soft-tissue infections increase in frequency, the use of newer antibiotics is becoming more common. This article reviews the use and cutaneous side effects of antivirals and new antibiotics with a focus on those relevant to the dermatologist.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
J Am Acad Dermatol
December 2020
Dermatology Unit, Virgen de las Nieves University Hospital, Granada, Spain; TECe19-Clinical and Translational Dermatology Investigation Group, Instituto Biosanitario, Granada, Spain; Dermatology Department, University of Granada, Granada, Spain.
The new coronavirus, severe acute respiratory syndrome coronavirus 2, is associated with a wide variety of cutaneous manifestations. Although new skin manifestations caused by COVID-19 are continuously being described, other cutaneous entities should also be considered in the differential diagnosis, including adverse cutaneous reactions to drugs used in the treatment of COVID-19 infections. The aim of this review is to provide dermatologists with an overview of the cutaneous adverse effects associated with the most frequently prescribed drugs in patients with COVID-19.
View Article and Find Full Text PDFTamiflu: what dermatologists need to know.
J Drugs Dermatol
January 2010
Manhattan Dermatology Associates, USA.
This article is a review of this winter's common infections and their treatments. As infectious agents become more aggressive and more resistant, new medications are needed to fight them. The recent outbreak of the H1N1 ("swine flu") influenza strain has increased, by several-fold, the use of the oral antiviral Tamiflu (oseltamivir) and Relenza (zenavimir).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!